Welcome to our dedicated page for ACCUSTEM SCIENCES news (Ticker: ACUT), a resource for investors and traders seeking the latest updates and insights on ACCUSTEM SCIENCES stock.
AccuStem Sciences Inc (ACUT) is a biotechnology innovator advancing stem cell research and regenerative medicine solutions. This page provides investors and industry professionals with direct access to the company's official announcements, financial updates, and scientific developments.
Track ACUT's progress through curated press releases covering clinical trial milestones, regulatory filings, and strategic partnerships. Our repository ensures you stay informed about advancements in cellular therapies and biotechnological innovations without speculative commentary.
Discover updates across key categories including quarterly earnings reports, intellectual property developments, and collaborative research initiatives. Each entry is timestamped for reference and formatted for clarity across devices.
Bookmark this page for streamlined access to AccuStem's evolving story in medical science. Verify critical information directly from primary sources before making data-driven decisions.
AccuStem Sciences (OTCQB: ACUT) and EmeritusDX have expanded their strategic partnership to commercialize the MSC test for lung cancer screening. The test analyzes 24 microRNAs to differentiate between high and low-risk lung nodules identified through low-dose computed tomography (LDCT).
The partnership aims to enhance lung nodule stratification accuracy, improve patient outcomes, and reduce healthcare costs. The companies plan to launch the MSC test in US clinics in 2026, targeting the 1.6 million patients diagnosed annually with lung nodules in the United States.
The collaboration will utilize EmeritusDX's CLIA-certified laboratory and commercial infrastructure alongside AccuStem's cancer screening technologies. Both companies will pursue reimbursement strategies to broaden access to the MSC test.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased an additional 5,000 shares of ACUT stock in the open market. This acquisition increases Cerrone's total holdings to 4,915,759 shares of the company.
AccuStem Sciences (OTCQB: ACUT) has signed a development agreement to access blood samples from the Rete Italiana di Screening Polmonare (RISP) clinical trial for its microRNA Signature Classifier (MSC) test development. The trial spans 18 centers in Italy.
The MSC test analyzes 24 miRNAs in plasma samples from patients with lung nodules to enhance low dose computed tomography (LDCT) screening accuracy. The MILD trial showed that combining MSC with LDCT could reduce false positive rates by a factor of five. The test has been validated across 5,000+ patients in multiple prospective trials.
The agreement includes statistical and analytical support to help AccuStem establish and commercialize the MSC test in the US, with a planned launch in 2026. The technology aims to improve patient triage, enhance outcomes, and reduce healthcare costs when used in conjunction with LDCT screening.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, announced that Board Chairman Gabriele Cerrone has purchased 38,000 additional company shares in the open market. This acquisition increases Cerrone's total holdings to 4,910,759 shares.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that Board Chairman Gabriele Cerrone has increased his stake in the company. The Chairman purchased 152,802 additional ACUT shares through open market transactions, bringing his total shareholding to 4,872,759 shares.
AccuStem Sciences (OTCQB: ACUT) announces plans to launch its microRNA Signature Classifier (MSC) blood test for lung cancer screening in the US. The test will initially target 1.6 million patients diagnosed yearly with nodules, with potential expansion to 15 million at-risk patients qualifying for annual screening.
The MSC test, developed at Istituto Nazionale Tumori, has been evaluated in over 5,000 patients across multiple clinical trials. When combined with low dose computed tomography (LDCT), MSC reduced false positive rates from 19.4% to 3.7%. The BioMILD trial showed MSC+ patients are four times more likely to have or develop lung cancer compared to MSC- patients.
AccuStem aims to commercialize the test in the US in 2026, potentially reducing unnecessary lung biopsies and healthcare costs. The company sees this as a significant opportunity to improve care outcomes for patients with lung nodules and plans to expand its use as a pre-screening tool before LDCT.
AccuStem Sciences (OTCQB: ACUT) has acquired the license for the proprietary microRNA Signature Classifier (MSC) test, a blood-based lung cancer screening technology. The test, developed by researchers at Istituto Nazionale Tumori (INT), evaluates 24 micro RNAs to enhance the accuracy of low-dose computed tomography (LDCT) in patients with pulmonary nodules.
Published data demonstrates that patients who test positive for both MSC and LDCT have a 30-fold higher cumulative lung cancer incidence compared to those negative for both tests. The combination of MSC with LDCT shows a five-fold reduction in false positives versus LDCT alone, potentially leading to improved outcomes and reduced healthcare costs.
The acquisition terms include issuing 3,750,000 common shares of AccuStem, with a 13-month resale restriction period. The company plans to launch the MSC test in the US in 2026.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that its Board Chairman, Gabriele Cerrone, has acquired an additional 100,000 ACUT shares through open market purchases. Following this transaction, Cerrone's total shareholding has increased to 4,719,957 shares.
FAQ
What is the current stock price of ACCUSTEM SCIENCES (ACUT)?
What is the market cap of ACCUSTEM SCIENCES (ACUT)?
